✦ LIBER ✦

Mitoxantrone and high-dose etoposide for patients with relapsed or refractory acute leukemia

✍ Scribed by Susan O'Brien; Kantarjian Hagop; Elihu Estey; Charles Koller; Miloslav Beran; Kenneth McCredie; Michael Keating

Publisher: John Wiley and Sons
Year: 1991
Tongue: English
Weight: 420 KB
Volume: 68
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(19910815)68:4<691::aid-cncr2820680404>3.0.co;2-z

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Mitoxantrone for refractory and relapsed

Mitoxantrone for refractory and relapsed acute leukemia

✍ Werner R. Bezwoda; Cano Bernasconi; Robert M. Hutchinson; David A. Winfield; Rob 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 473 KB 👁 1 views

Sequential intermediate-dose cytosine ar

Sequential intermediate-dose cytosine arabinoside and mitoxantrone for patients with relapsed and refractory acute myelocytic leukemia

✍ Paolo Alberto Paciucci; Janet Cuttner; James F. Holland 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 389 KB

High-dose liposomal daunorubicin and hig

High-dose liposomal daunorubicin and high-dose cytarabine combination in patients with refractory or relapsed acute myelogenous leukemia

✍ Jorge Cortes; Elihu Estey; Susan O'Brien; Francis Giles; Yu Shen; Charles Koller 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 89 KB 👁 1 views

## Background: Liposomal encapsulation of daunorubicin (daunoxome, dnx; nexstar pharmaceutical, boulder, co) changes the pharmacology profile to increase delivery to tumor sites and decrease toxicity. the authors investigated the effect of daunorubicin in combination with ara-c in patients with ref

High-dose cyclophosphamide and etoposide

High-dose cyclophosphamide and etoposide for patients with refractory acute myeloid leukemia: A case series

✍ Jeffrey Talbot; David A. Rizzieri; Carlos M. DeCastro; Joseph O. Moore; Patrick 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 263 KB

Mitoxantrone, etoposide, and cytarabine

Mitoxantrone, etoposide, and cytarabine plus cyclosporine for patients with relapsed or refractory acute myeloid leukemia : An Eastern Cooperative Oncology Group pilot study

✍ Martin S. Tallman; Sandra Lee; Branimir I. Sikic; Elisabeth Paietta; Peter H. Wi 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 115 KB 👁 1 views

## Background: One potential mechanism of drug resistance to chemotherapy is the overexpression of multidrug resistance (mdr) genes coding for p-glycoprotein (p-gp), which leads to reduced intracellular retention of chemotherapy. this study tested the efficacy and toxicity of mitoxantrone, etoposid

Mitoxantrone and high-dose cytosine arab

Mitoxantrone and high-dose cytosine arabinoside for the treatment of refractory acute lymphocytic leukemia

✍ Hagop M. Kantarjian; Ronald L. Walters; Michael J. Keating; Elihu H. Estey; SUSA 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 447 KB 👁 1 views

Twenty-five adult patients with refractory acute lymphocytic leukemia received salvage therapy with mitoxantrone 5 mg/m2 intravenously over 1 hour daily for 5 days and cytosine arabinoside 3 g/m2 intravenously over 2 hours every 12 hours for six doses. Overall, nine patients (36%) achieved complete